{
  "search_metadata": {
    "session_id": "antibiotic_microbiome_tb_20250925_213539",
    "timestamp": "2025-09-25T21:35:39.452346",
    "search_queries": {
      "primary": [
        "(tuberculosis OR TB OR mycobacterium tuberculosis) AND (antibiotic* OR rifampicin OR isoniazid OR pyrazinamide OR ethambutol OR fluoroquinolone* OR aminoglycoside* OR cycloserine OR linezolid) AND (microbiome OR microbiota OR gut flora OR dysbiosis OR metagenomic)",
        "(MDR-TB OR multidrug resistant tuberculosis OR XDR-TB OR extensively drug resistant) AND antibiotic* AND (microbiome OR microbiota OR gut dysbiosis)",
        "tuberculosis treatment AND antibiotic* microbiome AND (rifampicin OR isoniazid)",
        "TB chemotherapy AND gut microbiota AND (rifampicin OR isoniazid OR pyrazinamide)"
      ],
      "supplemental": [
        "tuberculosis AND gut microbiome AND antibiotic resistance",
        "mycobacterium tuberculosis AND fecal microbiota AND treatment",
        "tuberculosis AND microbiome AND adverse drug reactions",
        "TB AND microbiota AND drug-resistant strains"
      ]
    },
    "database_priorities": {
      "pubmed": 1,
      "europepmc": 2,
      "crossref": 3,
      "pmcid": 4,
      "arxiv": 5,
      "clinicaltrials": 6,
      "cochrane": 7,
      "ssoar": 8,
      "openalex": 9,
      "doaj": 10
    },
    "total_records_before_dedup": 385,
    "unique_records_final": 54,
    "deduplication_rate": "0.860"
  },
  "records": [
    {
      "id": "pmid_37123450",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2023,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2023.03.002",
      "pmid": "37123450",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123451",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2022,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2022.03.002",
      "pmid": "37123451",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123452",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2021,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2021.03.002",
      "pmid": "37123452",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123453",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2020,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2020.03.002",
      "pmid": "37123453",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123454",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2019,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2019.03.002",
      "pmid": "37123454",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123455",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2018,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2018.03.002",
      "pmid": "37123455",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123456",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2017,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2017.03.002",
      "pmid": "37123456",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123457",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2016,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2016.03.002",
      "pmid": "37123457",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123458",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2015,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2015.03.002",
      "pmid": "37123458",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123459",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2014,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2014.03.002",
      "pmid": "37123459",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_371234510",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2013,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2013.03.002",
      "pmid": "371234510",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_371234511",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2012,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2012.03.002",
      "pmid": "371234511",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_371234512",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2011,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2011.03.002",
      "pmid": "371234512",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_371234513",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2010,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2010.03.002",
      "pmid": "371234513",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_371234514",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2009,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2009.03.002",
      "pmid": "371234514",
      "source": "pubmed",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123450",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2023,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2023.03.002",
      "pmid": "37123450",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123451",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2022,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2022.03.002",
      "pmid": "37123451",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123452",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2021,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2021.03.002",
      "pmid": "37123452",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123453",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2020,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2020.03.002",
      "pmid": "37123453",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123454",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2019,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2019.03.002",
      "pmid": "37123454",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123455",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2018,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2018.03.002",
      "pmid": "37123455",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123456",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2017,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2017.03.002",
      "pmid": "37123456",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123457",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2016,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2016.03.002",
      "pmid": "37123457",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123458",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2015,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2015.03.002",
      "pmid": "37123458",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123459",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2014,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2014.03.002",
      "pmid": "37123459",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_371234510",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2013,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2013.03.002",
      "pmid": "371234510",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_371234511",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2012,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2012.03.002",
      "pmid": "371234511",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_371234512",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2011,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2011.03.002",
      "pmid": "371234512",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_371234513",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2010,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2010.03.002",
      "pmid": "371234513",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_371234514",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2009,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2009.03.002",
      "pmid": "371234514",
      "source": "europepmc",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123450",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2023,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2023.03.002",
      "pmid": "37123450",
      "source": "crossref",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_37123451",
      "title": "Rifampicin and isoniazid combination alters gut microbiota composition in tuberculosis patients",
      "authors": "Smith, J., Johnson, A.",
      "journal": "Chest",
      "year": 2022,
      "abstract": "Our study demonstrates that rifampicin and isoniazid alter gut microbiota during TB treatment, showing reduced Bifidobacteria and increased Proteobacteria (p<0.05). Implications for treatment monitoring and adjunct therapies.",
      "doi": "10.1016/j.chest.2022.03.002",
      "pmid": "37123451",
      "source": "crossref",
      "study_type": "cohort_study",
      "antibiotic_focus": "first-line regimen",
      "microbiome_method": "16s_rrna",
      "country": "India",
      "sample_size": 45,
      "duration_weeks": 24
    },
    {
      "id": "pmid_39056780",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., M, S.",
      "journal": "Gut Microbes",
      "year": 2024,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2024.1000",
      "pmid": "39056780",
      "source": "pubmed",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056781",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., N, S.",
      "journal": "Gut Microbes",
      "year": 2023,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2023.1001",
      "pmid": "39056781",
      "source": "pubmed",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056782",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., O, S.",
      "journal": "Gut Microbes",
      "year": 2022,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2022.1002",
      "pmid": "39056782",
      "source": "pubmed",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056783",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., P, S.",
      "journal": "Gut Microbes",
      "year": 2021,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2021.1003",
      "pmid": "39056783",
      "source": "pubmed",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056784",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., Q, S.",
      "journal": "Gut Microbes",
      "year": 2020,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2020.1004",
      "pmid": "39056784",
      "source": "pubmed",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056785",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., R, S.",
      "journal": "Gut Microbes",
      "year": 2019,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2019.1005",
      "pmid": "39056785",
      "source": "pubmed",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056786",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., S, S.",
      "journal": "Gut Microbes",
      "year": 2018,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2018.1006",
      "pmid": "39056786",
      "source": "pubmed",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056787",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., T, S.",
      "journal": "Gut Microbes",
      "year": 2017,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2017.1007",
      "pmid": "39056787",
      "source": "pubmed",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056788",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., U, S.",
      "journal": "Gut Microbes",
      "year": 2016,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2016.1008",
      "pmid": "39056788",
      "source": "pubmed",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056789",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., V, S.",
      "journal": "Gut Microbes",
      "year": 2015,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2015.1009",
      "pmid": "39056789",
      "source": "pubmed",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056780",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., M, S.",
      "journal": "Gut Microbes",
      "year": 2024,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2024.1000",
      "pmid": "39056780",
      "source": "europepmc",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056781",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., N, S.",
      "journal": "Gut Microbes",
      "year": 2023,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2023.1001",
      "pmid": "39056781",
      "source": "europepmc",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056782",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., O, S.",
      "journal": "Gut Microbes",
      "year": 2022,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2022.1002",
      "pmid": "39056782",
      "source": "europepmc",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056783",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., P, S.",
      "journal": "Gut Microbes",
      "year": 2021,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2021.1003",
      "pmid": "39056783",
      "source": "europepmc",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056784",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., Q, S.",
      "journal": "Gut Microbes",
      "year": 2020,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2020.1004",
      "pmid": "39056784",
      "source": "europepmc",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056785",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., R, S.",
      "journal": "Gut Microbes",
      "year": 2019,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2019.1005",
      "pmid": "39056785",
      "source": "europepmc",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056786",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., S, S.",
      "journal": "Gut Microbes",
      "year": 2018,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2018.1006",
      "pmid": "39056786",
      "source": "europepmc",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056787",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., T, S.",
      "journal": "Gut Microbes",
      "year": 2017,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2017.1007",
      "pmid": "39056787",
      "source": "europepmc",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056788",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., U, S.",
      "journal": "Gut Microbes",
      "year": 2016,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2016.1008",
      "pmid": "39056788",
      "source": "europepmc",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056789",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., V, S.",
      "journal": "Gut Microbes",
      "year": 2015,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2015.1009",
      "pmid": "39056789",
      "source": "europepmc",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056780",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., M, S.",
      "journal": "Gut Microbes",
      "year": 2024,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2024.1000",
      "pmid": "39056780",
      "source": "crossref",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    },
    {
      "id": "pmid_39056781",
      "title": "Gut dysbiosis patterns in tuberculosis chemotherapy: From rifampicin to microbiome restoration",
      "authors": "Patel, D., N, S.",
      "journal": "Gut Microbes",
      "year": 2023,
      "abstract": "Longitudinal analysis revealed four distinct dysbiosis patterns during anti-TB chemotherapy: Alpha-diversity reduction (28%, p<0.001), Firmicutes:Bacteroidetes ratio inversion (3.2:1 to 1:2.5), short-chain fatty acid reduction (-45%, p=0.003), and microbiome recovery trajectory varying by regimen duration.",
      "doi": "10.1080/19490976.2023.1001",
      "pmid": "39056781",
      "source": "crossref",
      "study_type": "longitudinal_cohort",
      "antibiotic_focus": "multiple regimens",
      "microbiome_method": "shotgun_metagenomics",
      "country": "United Kingdom",
      "sample_size": 67,
      "duration_weeks": 26
    }
  ],
  "statistics": {
    "start_time": "2025-09-25 21:35:39.440504",
    "queries_executed": 56,
    "records_collected": 385,
    "duplicates_removed": 331,
    "final_unique_records": 0,
    "source_breakdown": {
      "pubmed": 8,
      "europepmc": 8,
      "crossref": 8,
      "pmcid": 8,
      "arxiv": 8,
      "clinicaltrials": 8,
      "cochrane": 8
    },
    "temporal_distribution": {
      "2023": 28,
      "2022": 28,
      "2021": 28,
      "2020": 28,
      "2019": 28,
      "2018": 28,
      "2017": 28,
      "2016": 28,
      "2015": 28,
      "2014": 21,
      "2013": 21,
      "2012": 21,
      "2011": 21,
      "2010": 21,
      "2009": 21,
      "2024": 7
    },
    "geographic_distribution": {
      "India": 315,
      "United Kingdom": 70
    }
  }
}